401 related articles for article (PubMed ID: 11245458)
1. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
2. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
Lin X; Trang J; Okuda T; Howell SB
Clin Cancer Res; 2006 Jan; 12(2):563-8. PubMed ID: 16428501
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair.
Kondo A; Safaei R; Mishima M; Niedner H; Lin X; Howell SB
Cancer Res; 2001 Oct; 61(20):7603-7. PubMed ID: 11606400
[TBL] [Abstract][Full Text] [Related]
4. Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.
Vernole P; Tedeschi B; Tentori L; Levati L; Argentin G; Cicchetti R; Forini O; Graziani G; D'Atri S
Mutat Res; 2006 Feb; 594(1-2):63-77. PubMed ID: 16139849
[TBL] [Abstract][Full Text] [Related]
5. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
Cenni B; Kim HK; Bubley GJ; Aebi S; Fink D; Teicher BA; Howell SB; Christen RD
Br J Cancer; 1999 May; 80(5-6):699-704. PubMed ID: 10360646
[TBL] [Abstract][Full Text] [Related]
6. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.
Lin X; Howell SB
Mol Cancer Ther; 2006 May; 5(5):1239-47. PubMed ID: 16731756
[TBL] [Abstract][Full Text] [Related]
7. p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide.
Lin X; Ramamurthi K; Mishima M; Kondo A; Howell SB
Mol Pharmacol; 2000 Dec; 58(6):1222-9. PubMed ID: 11093757
[TBL] [Abstract][Full Text] [Related]
8. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
Cancer Res; 2003 Jun; 63(12):3241-6. PubMed ID: 12810654
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
10. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
11. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin.
Lin X; Howell SB
Mol Pharmacol; 1999 Aug; 56(2):390-5. PubMed ID: 10419559
[TBL] [Abstract][Full Text] [Related]
12. Analysis of microsatellite instability in acquired drug-resistance human tumor cell lines.
Picard SF; Franco N; Sergent C; Chauffert B; Lizard-Nacol S
Oncol Rep; 2002; 9(5):971-6. PubMed ID: 12168057
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
Hawkins DS; Demers GW; Galloway DA
Cancer Res; 1996 Feb; 56(4):892-8. PubMed ID: 8631030
[TBL] [Abstract][Full Text] [Related]
14. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
15. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of geno- and cytotoxicity of methylnitrosourea on MMR-proficient and MMR-deficient human tumor cell lines].
Tronov VA; Kramarenko II; Smirnova TD; Terekhov SM
Tsitologiia; 2006; 48(1):19-27. PubMed ID: 16568831
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage.
Vikhanskaya F; Colella G; Valenti M; Parodi S; D'Incalci M; Broggini M
Clin Cancer Res; 1999 Apr; 5(4):937-41. PubMed ID: 10213232
[TBL] [Abstract][Full Text] [Related]
19. Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents.
Vernole P; Pepponi R; D'Atri S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):185-92. PubMed ID: 12827294
[TBL] [Abstract][Full Text] [Related]
20. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
